Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter   Weekly View October 2, 2026 From the desk of Priya Ranade Good mornin

Report finds new therapies clinically comparable to currently available generic treatments and provides recommendation for pricing.

Cell and gene therapies are expanding to address more than just rare diseases. Learn what employers need to know about access, affordability, and value.

Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter   Weekly View September 18, 2026 From the desk of Priya Ranade Good mor

Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter   Weekly View September 18, 2026 From the desk of Priya Ranade Good mor

Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter   Weekly View September 11, 2026 From the desk of Priya Ranade Good mor

Report will be submitted as public comment for Medicare Drug Price negotiation Program

Groups to analyze launch prices and patient access of newly approved FDA treatments.

Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter   Weekly View August 28, 2026 From the desk of Priya Ranade Good mornin

New members represent a variety of perspectives across the health care system

Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter   Weekly View August 21, 2026 From the desk of Priya Ranade Good mornin

Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter   Weekly View August 14, 2026 From the desk of Priya Ranade Good mornin

Public comment period now open until September 9, 2026; Requests to make oral comment during public meeting also being accepted

Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter   Weekly View August 7, 2026 From the desk of Priya Ranade Good morning

Public comment period now open until August 25, 2026; Requests to make oral comment during public meeting also being accepted.

Independent appraisal committee unanimously found that Covid-19 vaccination provides a net health benefit for many US subpopulations.

Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter   Weekly View July 24, 2026 From the desk of Priya Ranade Good morning,

Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter Programming note: Weekly View will be back in your inbox on July 24th!

Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter Programming note: The Weekly View will be back in your inbox on July 10

Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter   Weekly View June 18, 2026 From the desk of Priya Ranade Good morning,

Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter   Weekly View June 12, 2026 From the desk of Priya Ranade Good morning,

ICER analyzed the impact of vaccination on several US subpopulations; at current prices, vaccines are cost effective.

Manufacturer setting a price for oveporexton to align with value would help promote broad patient access.

Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter   Weekly View June 5, 2026 From the desk of Priya Ranade Good morning,

For serious conditions with high unmet need, earlier access to promising treatments can be worth the risk of greater uncertainty. But achieving this balance demands trust.

Report will be subject of New England CEPAC meeting in January 2027; Draft Scoping Document open to public comment until June 16, 2026.

Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter   Weekly View May 21, 2026 From the desk of Priya Ranade Good morning,

Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter   Weekly View May 15, 2026 From the desk of Priya Ranade Good morning,

Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter   Weekly View May 8, 2026 From the desk of Priya Ranade Good morning, e

Oveporexton provides a net health benefit compared to currently available treatments; therapy would be cost effective if priced between $50,400 and $59,400 per year.

The ISPOR 2026 Conference will feature several ICER speakers. See our full lineup below:

New paper, developed with input from diverse stakeholders, outlines policy options to strengthen the FDA pathway.